Epiceram over the Counter<font color="#ffff00" size=14> ;
OTC moisturizers are just as clinical and less expensive than prescribing skin care barriers for the children.... - PUBLIC MED
There have been no trials to evaluate both the clinically effectiveness and cost-effectiveness of these ethical products against OTC-dispensers. APPLICATION: The objective of this trial is to evaluate the effectiveness and cost-effectiveness of a Glycyrrhetinic Accretion Scream (BRC-Gly, Atopiclair®), a Ceramide-Dominant Accretion Scream (BRC-Cer, EpiCeram®) and an OTC Oil-based Moisturizing Agent (OTC-Pet, Aquaphor Healing Saltment®) as a single therapy for minor to moderately severe AD in infants.
MODES: Thirty-nine AD aged 2-17 years with light to moderately severe AD were randomly assigned 1:1:1 to one of three therapies - BRC-Gly, BRC-Cer, or OTC-Pet - with directions to use the therapy three days a day for three consecutive weeks. RESULTS: No significant statistical differences for effectiveness evaluation were found between the three groups at any point in tim.
OTC-Pet proved to be at least 47x cheaper than BRC-Gly or BRC-Cer. A relatively small number of 39 volunteers was not enough to make OTC-Pet the better choice for ADT. OTC Pet is as efficient as BRC-Gly and BRC-Cer in the light to medium AD segment and at least 47x cheaper.
Compare the efficacy and cost-effectiveness of aquaphore with atopic and EpiCeram in children with mild to moderate atopic dermatitis.
Fixing barriers in case of allergic inflammation
AD sufferers are generally known to have very dehydrated skins as part of their disease. Being such, a very important part of the discussion on the AD therapy involves the importance of humidifying the hide on a periodic base in order to try to alleviate the dehydration. It has been assumed for many years that infection in the dermis causes a disorder and degradation of the dermal membrane.
It has been assumed that this infection is due to the genetics of these AD people. New ( and older ) evidence is available suggesting that the original site of the anomaly lies within the cuticle itself, with primal barriers disorder, which then allows the entry of any allergen, irritant, etc. that form the causal path of infection that eventually worsens things.
Approximately 50% of AD sufferers have a genetically engineered variant that lowers their level of filtration in the epidermis film. The degradation product of Filaggrin forms the "Natural Moisturizing Factor", which consists of protein, acid and moisturizers that provide the moisture to the epidermis. Without the use of filtration in a patient such as Ithyosis and AD patient, the absence of self-wetting capability exacerbates the malfunction of the lateral wall of the epidermis.
In Canada, there is now a range of skinner' wall cream products that target replenishing the standard components of the lipids and trying to fix the barriers. They are different from conventional moisturisers or emolients used to isolate hydration from the epidermis and create a single layer of barriers.
All of these dermal barriers have different levels of ceramide, free acid and free acid levels, which are the constituents of the lipids within the cell. Epiceram corrective wrinkle lotions are available both over the counter and over the counter (CeraVe Cleaner, Body Wash and Body Wash, Cetaphil Restoraderm Cleaner and Lotion).
In a 2009 randomised, investigator-blinded trial, Epiceram was likened to a low mean efficacy topically administered serum hormone gel (fluticasone propionate 0.05%) in 121 intermediate to advanced AD disease survivors over 28 consecutive day. Fewer Epiceram arms also needed to be treated with replacement treatment with steroidal drugs, making them a candidate for single use. A further trial in 2011 investigated Epiceram as single agent treatment or in conjunction with various topically administered depressants.
Out of the 207 patiënten 54% were in weeks 3, in both arms, clear or almost clear, especially those with minor ADD. In 2008, SeraVe released the use of its cleaner and moisturizer in 60 AD moderately to mildly AD resistant people. They were used as additive treatment in the treatment of AD with topically applied creme Fluocinonid 0.05% to see if VitraVe could decrease the length of AD symptoms.
In fact, by adding the CeraVe product, the morbidity clearing could be increased from 15% (with a gentle detergent, without mositurisers and alone steroids) to 76% (if used in combination with the CeraVe detergent and cream). Now if I have a patients with AD who does all those things to the best of their ability to ( and recall they need periodic messages ), I suggest they try one of the new dermal barriers Repair Creams.
They can be used generously anywhere or in hotspots that always burn up. They are only one part of the therapeutic scheme we use to treat AD sufferers, but they are a newer instrument that can bring significant benefits, especially in combination with proactive medicinal treatments.
Withers M et al. Canadian Consensus on the Therapy of Skin Barriers and Neurodermatitis.